All News

NUS Launches Master in Healthy Longevity Programme

By Sandy Martin•November 17, 2026

The National University of Singapore is launching full-time and professional master’s pathways in healthy longevity, formalising training across ageing biology, clinical research, policy, finance and ethics.

The National University of Singapore (NUS) is turning healthy longevity into a formal postgraduate discipline. Its Yong Loo Lin School of Medicine will offer a Master in Healthy Longevity through two distinct pathways: a one-year, full-time programme taught on site and a two-year, part-time programme combining online and in-person learning for working professionals.

The scope extends beyond conventional medical training to people involved in policy, investment and innovation. A report on the programme launch describes it as open to investors and policymakers as well as clinicians, and says applications for the announced intake close on 30 November.

This is an educational development rather than a new clinical or population-health finding. Its importance lies in how NUS is defining the knowledge needed to work responsibly in a field where ageing biology, diagnostic technology, clinical trials and commercial activity increasingly overlap—but where the strength of evidence varies substantially between topics.

Two pathways into an emerging discipline

The full-time pathway is aimed at early-career students and uses on-site teaching over one year. The professional pathway spreads study over two years and uses blended delivery, making it more accessible to people already working in healthcare, research, government or industry.

That structure reflects the unusually broad set of professions now engaging with healthy longevity. Researchers may be concerned with cellular pathways and experimental models; clinicians with diagnosis, risk and patient care; policymakers with prevention, access and the organisation of ageing societies; and industry participants with product development, evidence standards and finance.

Bringing these groups into a shared academic programme could help establish a common vocabulary. Terms such as “biomarker”, “hallmark of ageing” and “gerotherapeutic” can carry different meanings in a laboratory, clinic, regulatory discussion or investor presentation. Graduate-level training offers an opportunity to connect those meanings to study design and evidentiary limits rather than treating longevity as a single, settled field.

From ageing biology to trials, policy and finance

The published curriculum sets out five core courses: Foundations of Healthy Longevity, Hallmarks of Ageing, Gerodiagnostics, Gerotherapeutics, and Building Healthy Longevity: Strategy and Ethics.

Together, those subjects trace a path from basic biology to implementation. The hallmarks framework is commonly used to organise biological processes implicated in ageing. Gerodiagnostics concerns approaches intended to measure or characterise aspects of ageing, while gerotherapeutics covers interventions directed at age-related mechanisms or their consequences. Strategy and ethics place those scientific questions within decisions about development, access, governance and responsible use.

The wider course list includes preclinical geroscience, clinical trials, advanced gerodiagnostics and gerotherapeutics, finance and innovation, and global policy. An eight-unit capstone project gives students a route to integrate those areas around a defined problem.

The inclusion of both preclinical research and clinical trials is particularly consequential. Findings in cells or animal models can identify mechanisms and generate testable hypotheses, but they do not by themselves establish that an intervention is effective or safe in people. Human observational research can reveal relationships between behaviours, biological characteristics and later-life outcomes, yet association alone cannot show that changing one factor will cause a person to live longer or remain healthier.

Interventional human trials provide a stronger basis for causal conclusions, although their meaning still depends on design, duration, participant selection and the outcome measured. Teaching those distinctions is central to evaluating claims in a field that ranges from foundational biology to consumer-facing products.

Healthy longevity is a systems problem

The breadth of the degree also reflects the nature of longevity itself. Exceptional survival is not explained by one pathway or behaviour. A recent review of exceptional longevity describes it as a multifactorial phenotype shaped by genetic, biological, lifestyle, psychosocial and environmental influences.

That complexity has practical implications. A molecular process that appears important in a laboratory may interact in people with nutrition, physical activity, infection, healthcare access, social conditions and numerous other exposures accumulated over decades. Even a technically accurate measure of one biological pathway may therefore capture only a limited part of an individual’s ageing trajectory.

The same review found that evidence connecting mechanisms such as DNA repair, inflammatory regulation and mitochondrial function with exceptional longevity remains predominantly correlational rather than causal. These mechanisms are scientifically plausible and actively studied, but plausibility should not be confused with proof that manipulating them will improve human outcomes.

This makes the programme’s coverage of diagnostics, trials, ethics and policy more than academic breadth. Biomarkers require validation for a defined use. Candidate interventions need appropriately controlled human studies. Policy decisions require evidence that applies to populations, while financing and innovation decisions must account for scientific uncertainty as well as commercial potential.

Professional training may raise the field’s standards

Healthy longevity is often discussed as though it were a single market or medical speciality. In practice, it sits across gerontology, preventive medicine, molecular biology, public health, data science, regulation and social policy. No master’s degree can resolve the field’s unanswered scientific questions, but a structured programme can teach professionals how to frame them more precisely.

For clinicians and researchers, that may mean distinguishing exploratory biomarkers from tools ready for clinical use, or separating preclinical signals from evidence of benefit in humans. For policymakers, it may mean evaluating whether an innovation can improve health at population scale and whether access will be equitable. For investors and product developers, it may mean interrogating trial endpoints, validation standards and regulatory pathways before treating a biological hypothesis as a viable intervention.

NUS’s programme is therefore notable less as an endorsement of any particular longevity treatment than as evidence that the field is becoming institutionalised. By placing biological mechanisms alongside clinical evaluation, finance, global policy and ethics, the university is defining healthy longevity as a domain that demands both scientific literacy and judgement.

That is a useful development for a sector in which interest is moving faster than causal human evidence. The strongest contribution of postgraduate training may be to produce professionals who can recognise promising science without overstating it—and who understand that extending healthy years requires more than identifying an intriguing mechanism.